RE:RE:RE:RE:RE:Just to add to the credibility talkWhat would they do when they recommend a company to their clients and the company have a set back they would try to brush it off not admitting they were wrong.
Now we have the opposite situation as for THTX the analysts covering the company have been refusing to account for their R&D programs or not giving it the credit it deserves so when the company comes out and clearly proof them wrong they refuse to adjust their estimates as they will look foolish by doing that, that's why I think this whole thing is rigged therefore the company should shift the focus to retail segment once the SP is much higher the legacy analysts and new analysts will be joining the bandwagon.
jeffm34 wrote: Interesting reading the Mersana article and the analysts reaction to bad news from their trials. They have bad news and the analysts try and keep a positive outlook despite the data. TH has good news (Nash phase 3 trial to proceed) and the analysts throw cold water on it.